Obesity is a growing health concern, with a significant global rise over the past few decades. It not only affects your body weight but also contributes to a variety of health problems like diabetes, heart disease, joint issues, and even certain cancers. While many people turn to medication for help in managing obesity, a new study has raised important questions about the mental health side effects of certain obesity medications.
What Are GLP-1 Medications?
GLP-1 (Glucagon-Like Peptide-1) receptor agonists are a class of medications that have become popular for treating obesity. Two commonly prescribed GLP-1 drugs are Liraglutide and Semaglutide. These medications help reduce weight by decreasing appetite and controlling blood sugar levels, making them useful for people with obesity and those struggling with type 2 diabetes.
The New Study: Mental Health Risks of GLP-1 Medications In People With Obesity
A recent study conducted between 2015 and 2023 explored the link between GLP-1 medications and mental health conditions like depression, anxiety, and suicidal behavior in people with obesity. The study analyzed data from over 162,000 patients who were prescribed GLP-1 medications and compared them to those who weren’t on these drugs.
The Key Findings:
- Increased Risk of Psychiatric Disorders: People using GLP-1 medications had nearly twice the risk of developing any psychiatric disorder compared to those who weren’t using the medication.
- Major Depression: Those on GLP-1 drugs had a 195% higher risk of developing major depression.
- Anxiety: The risk of anxiety was increased by 108% in users of GLP-1 medications.
- Suicidal Behavior: There was a 106% increase in suicidal thoughts or attempts among those taking GLP-1 drugs.
These findings are concerning, particularly because people with obesity already face a higher risk of mental health issues like depression. The study’s results highlight the importance of doctors thoroughly assessing their patients’ mental health histories before prescribing these medications.
Why Are GLP-1 Medication Risks In Obese Patients Important?
While GLP-1 medications are effective in helping with weight loss and have been FDA-approved, this study shows they may have unintended mental health side effects, especially in people who are already at risk for conditions like depression or anxiety.
For people struggling with obesity, it’s important to weigh the benefits of weight loss and improved metabolic health against the potential risks to mental well-being. The study shows that the risk of developing mental health issues increases over time, making it crucial for patients on GLP-1 medications to be regularly monitored for any signs of depression, anxiety, or suicidal thoughts.
Who Is Most Affected By Negative GLP-1 Medication Risks?
The study also revealed that certain groups might be more vulnerable to these mental health effects:
- Women had a significantly higher risk of developing depression, with a 216% higher risk compared to men.
- Younger individuals (ages 18–49) were especially at risk for suicidal thoughts or attempts.
- People from different racial backgrounds also experienced varying levels of increased risks, with Black patients having a notably higher risk of anxiety and suicidal thoughts.
Considering A GLP-1 Medication For Weight Loss? What Do These Risks This Mean for You?
If you’re considering GLP-1 medications for weight loss, it’s important to talk to your healthcare provider about any existing mental health conditions. If you or someone in your family is on GLP-1 medications, be sure to monitor any changes in mood, energy levels, or thoughts about self-harm. Early intervention and support are key to managing these potential side effects.
Dr. Brown Discusses GLP-1 Medications And Negative Mental Health Impacts
Looking Ahead To GLP1-Medications And Mental Health Risks For Patients With Obesity
The study suggests that more research is needed to fully understand how GLP-1 medications impact mental health, particularly with long-term use. If you’re prescribed these medications, it’s essential to have ongoing conversations with your doctor about both physical and mental health, ensuring that you receive the right care for all aspects of your well-being.
At Idaho BMI, we’re committed to helping you manage your weight safely and effectively with bariatric surgery. If you have concerns about GLP-1 medications or any aspect of obesity treatment, don’t hesitate to reach out to the team managing your care for guidance and support.
If you’re interested in a long term and proven solution to weight loss and obesity related health conditions, consider scheduling a consultation with Idaho BMI. We are here to help! To take the first step toward a healthier future contact Idaho BMI in Boise, Idaho, today to learn more about your options and start your journey toward a happier, healthier you.
Sources:
- Kornelius, E., et al. (2024). “The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy.” Scientific Reports.
- Wadden, T. A., et al. (2020). “Liraglutide 3.0 mg and intensive behavioral therapy for obesity in primary care: the SCALE IBT randomized controlled trial.” Obesity, 28, 529-536.
